Contamination Issues Drove Drug Recalls to Record Levels in 2011
This article was originally published in The Gold Sheet
How contamination, sterility assurance, OOS and other issues caused drug recalls to spike again last year. What happened at Aidapak, H&P, Ben Venue, Hospira, Teva and other manufacturers to set a new record.
You may also be interested in...
Many of the 30 drug product firms that received FDA warning letters in 2016 were foreign cosmetics and hygiene manufacturers that appeared to need education on US GMP requirements. Another major focus in letters to drug product firms last year was sterility assurance in the US and abroad.
Huge recall numbers last year reflected FDA's continued enforcement of sterility assurance at compounding pharmacies, while generic and brand manufacturers dealt with particulate contamination and various out-of-specification issues.
Microbial and particulate contamination drove drug recalls to historic levels for a fifth year in 2014, FDA recall data shows. But the data still falters in identifying the weakest links in global pharmaceutical supply chain quality.